Literature DB >> 23838031

Batten disease: clinical aspects, molecular mechanisms, translational science, and future directions.

Sarah-Bianca Dolisca1, Mitali Mehta, David A Pearce, Jonathan W Mink, Bernard L Maria.   

Abstract

The neuronal ceroid lipofuscinoses, collectively the most common neurodegenerative disorders of childhood, are primarily caused by an autosomal recessive genetic mutation leading to a lysosomal storage disease. Clinically, these diseases manifest at varying ages of onset, and associated symptoms include cognitive decline, movement disorders, seizures, and retinopathy. The underlying cell biology and biochemistry that cause the clinical phenotypes of neuronal ceroid lipofuscinoses are still being elaborated. The 2012 Neurobiology of Disease in Children Symposium, held in conjunction with the 41st Annual Meeting of the Child Neurology Society, aimed to (1) provide a survey of the currently accepted forms of neuronal ceroid lipofuscinoses and their associated genetic mutations and clinical phenotypes; (2) highlight the specific pathology of Batten disease; (3) discuss the contemporary understanding of the molecular mechanisms that lead to pathology; and (4) introduce strategies that are being translated from bench to bedside as potential therapeutics.

Entities:  

Keywords:  Batten disease

Mesh:

Year:  2013        PMID: 23838031      PMCID: PMC3986921          DOI: 10.1177/0883073813493665

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  5 in total

1.  Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.

Authors:  Katherine R Smith; John Damiano; Silvana Franceschetti; Stirling Carpenter; Laura Canafoglia; Michela Morbin; Giacomina Rossi; Davide Pareyson; Sara E Mole; John F Staropoli; Katherine B Sims; Jada Lewis; Wen-Lang Lin; Dennis W Dickson; Hans-Henrik Dahl; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2012-05-17       Impact factor: 11.025

2.  CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide.

Authors:  K L Puranam; W X Guo; W H Qian; K Nikbakht; R M Boustany
Journal:  Mol Genet Metab       Date:  1999-04       Impact factor: 4.797

3.  Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth.

Authors:  Susan L Cotman; Vladimir Vrbanac; Lori-Anne Lebel; Richard L Lee; Kevin A Johnson; Leah-Rae Donahue; Allison M Teed; Kristen Antonellis; Roderick T Bronson; Terry J Lerner; Marcy E MacDonald
Journal:  Hum Mol Genet       Date:  2002-10-15       Impact factor: 6.150

4.  Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.

Authors:  Vivianna M Van Deerlin; Patrick M A Sleiman; Maria Martinez-Lage; Alice Chen-Plotkin; Li-San Wang; Neill R Graff-Radford; Dennis W Dickson; Rosa Rademakers; Bradley F Boeve; Murray Grossman; Steven E Arnold; David M A Mann; Stuart M Pickering-Brown; Harro Seelaar; Peter Heutink; John C van Swieten; Jill R Murrell; Bernardino Ghetti; Salvatore Spina; Jordan Grafman; John Hodges; Maria Grazia Spillantini; Sid Gilman; Andrew P Lieberman; Jeffrey A Kaye; Randall L Woltjer; Eileen H Bigio; Marsel Mesulam; Safa Al-Sarraj; Claire Troakes; Roger N Rosenberg; Charles L White; Isidro Ferrer; Albert Lladó; Manuela Neumann; Hans A Kretzschmar; Christine Marie Hulette; Kathleen A Welsh-Bohmer; Bruce L Miller; Ainhoa Alzualde; Adolfo Lopez de Munain; Ann C McKee; Marla Gearing; Allan I Levey; James J Lah; John Hardy; Jonathan D Rohrer; Tammaryn Lashley; Ian R A Mackenzie; Howard H Feldman; Ronald L Hamilton; Steven T Dekosky; Julie van der Zee; Samir Kumar-Singh; Christine Van Broeckhoven; Richard Mayeux; Jean Paul G Vonsattel; Juan C Troncoso; Jillian J Kril; John B J Kwok; Glenda M Halliday; Thomas D Bird; Paul G Ince; Pamela J Shaw; Nigel J Cairns; John C Morris; Catriona Ann McLean; Charles DeCarli; William G Ellis; Stefanie H Freeman; Matthew P Frosch; John H Growdon; Daniel P Perl; Mary Sano; David A Bennett; Julie A Schneider; Thomas G Beach; Eric M Reiman; Bryan K Woodruff; Jeffrey Cummings; Harry V Vinters; Carol A Miller; Helena C Chui; Irina Alafuzoff; Päivi Hartikainen; Danielle Seilhean; Douglas Galasko; Eliezer Masliah; Carl W Cotman; M Teresa Tuñón; M Cristina Caballero Martínez; David G Munoz; Steven L Carroll; Daniel Marson; Peter F Riederer; Nenad Bogdanovic; Gerard D Schellenberg; Hakon Hakonarson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Genet       Date:  2010-02-14       Impact factor: 38.330

Review 5.  Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses.

Authors:  Maria Kousi; Anna-Elina Lehesjoki; Sara E Mole
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.700

  5 in total
  13 in total

1.  Progress toward Fulfilling the Potential of Immunomodulation in Childhood Neurodegeneration?

Authors:  Jonathan D Cooper; Hemanth R Nelvagal
Journal:  Mol Ther       Date:  2017-06-16       Impact factor: 11.454

Review 2.  Aging in the canine and feline brain.

Authors:  Charles H Vite; Elizabeth Head
Journal:  Vet Clin North Am Small Anim Pract       Date:  2014-11-01       Impact factor: 2.093

Review 3.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

4.  Successful treatment of cannabinoid administration against refractory epilepsy in Batten disease: a case report.

Authors:  Fotini Georgiou; Panayiotis Maghsoudlou; Panagiotis Loukaidis; D Markoullaki; Christiana Giorgi; Ioanna Christodoulou; Chrystalla Matsentidou
Journal:  Neurol Sci       Date:  2020-09-30       Impact factor: 3.307

Review 5.  Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders.

Authors:  Kyeongsoon Kim; Hynda K Kleinman; Hahn-Jun Lee; Kalipada Pahan
Journal:  Orphanet J Rare Dis       Date:  2017-06-17       Impact factor: 4.123

6.  Aberrant Autophagy Impacts Growth and Multicellular Development in a Dictyostelium Knockout Model of CLN5 Disease.

Authors:  Meagan D McLaren; Sabateeshan Mathavarajah; William D Kim; Shyong Q Yap; Robert J Huber
Journal:  Front Cell Dev Biol       Date:  2021-07-05

Review 7.  Neuroinflammatory paradigms in lysosomal storage diseases.

Authors:  Megan E Bosch; Tammy Kielian
Journal:  Front Neurosci       Date:  2015-10-30       Impact factor: 4.677

8.  Neuronal Ceroid Lipofuscinoses: Connecting Calcium Signalling through Calmodulin.

Authors:  Sabateeshan Mathavarajah; Danton H O'Day; Robert J Huber
Journal:  Cells       Date:  2018-10-29       Impact factor: 6.600

9.  Spinal manifestations of CLN1 disease start during the early postnatal period.

Authors:  H R Nelvagal; J T Dearborn; J R Ostergaard; M S Sands; J D Cooper
Journal:  Neuropathol Appl Neurobiol       Date:  2020-09-07       Impact factor: 8.090

10.  CLN3, at the crossroads of endocytic trafficking.

Authors:  Susan L Cotman; Stéphane Lefrancois
Journal:  Neurosci Lett       Date:  2021-07-16       Impact factor: 3.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.